Healthcare business law · Updated

The Anti-Kickback Statute: what clinics selling GLP-1s and peptides need to know

The federal Anti-Kickback Statute makes it a felony to knowingly and willfully offer, pay, solicit or receive anything of value to induce or reward referrals, or the ordering or recommending of items or services, that a federal health care program pays for in whole or in part. The maximum is a $100,000 fine and 10 years in prison, and a claim that results from a kickback is a false claim. For a GLP-1 or peptide clinic the first question is whether any federal program pays: Medicare covers some GLP-1 uses, its GLP-1 Bridge has covered brand Wegovy, Zepbound KwikPen and Foundayo for weight management since July 1, 2026, and NC Medicaid again covers GLP-1s for obesity. A program paid only in cash is, in our reading, generally outside the federal statute, but the North Carolina Medical Board's position against referral fees and percentage fee splitting still applies.

Common GLP-1 and peptide clinic payments, and the rules that reach them (as of November 4, 2026)
PaymentFederal Anti-Kickback StatuteOther rules
A marketer or lead seller paid per patient, per consult or per prescriptionReached if any of the items or services are billed to a federal program. A fee that rises with the number of patients sent does not fit the personal services safe harbor, which bars pay set by the volume or value of referralsNC Medical Board: payment solely for a referral is unethical and prohibited by state law (G.S. 90-401)
A telehealth company paying prescribers per consult or per prescriptionVolume-based pay is one of OIG's suspect characteristics for telemedicine arrangements (July 20, 2022 alert)NC Medical Board: no prescribing on a questionnaire alone
A pharmacy paying a clinic, prescriber or marketer for the prescriptions it receivesA kickback where the prescriptions are federally reimbursed; payments from a pharmacy that mainly compounds are excluded from the outcomes-based payment protectionNC Medical Board referral-fee statement
A medical director or management company paid a percentage of the clinic's revenueThe personal services safe harbor needs pay set in advance, at fair market value, not reflecting federal program referralsNC Medical Board: a licensee "cannot share revenue on a percentage basis with a non-licensee" except as G.S. 55B-14(c) permits
Salaries of bona fide employeesProtected by the employee exception and safe harborEmployment terms still subject to the fee-splitting statement
Free items, waived copays or discounts for Medicare or Medicaid patientsThe beneficiary inducements law applies; OIG treats items worth no more than $15 each and $75 a year per patient, never cash, as nominalNot a general rule for cash patients
Payments for referrals to a laboratory (for example bundled lab panels)Not the only law: EKRA, 18 U.S.C. 220, reaches lab referrals under any public or private planEKRA: up to $200,000 and 10 years per occurrence
Federal penalties for health care kickbacks
LawWhat it reachesMaximum
42 U.S.C. 1320a-7b(b) (criminal)Knowing and willful kickbacks tied to items or services payable by a federal health care programFelony: $100,000 fine, 10 years, or both (raised from $25,000 and 5 years on February 9, 2018)
42 U.S.C. 1320a-7a(a)(7) (civil)The same acts, in an administrative case$100,000 per act in the statute, $127,973 after the inflation adjustment (45 CFR 102.3), plus up to 3 times the remuneration
42 U.S.C. 1320a-7b(g) (False Claims Act link)A claim that includes items or services resulting from a kickbackTreated as a false or fraudulent claim under the False Claims Act
42 U.S.C. 1320a-7(b)(7) (exclusion)Anyone the Secretary finds committed a kickback actExclusion from every federal health care program (permissive)
42 U.S.C. 1320a-7a(a)(5) (beneficiary inducements)Remuneration likely to influence a Medicare or state health care program patient's choice of provider$25,595 per act after the inflation adjustment (45 CFR 102.3)
18 U.S.C. 220 (EKRA)Kickbacks for referrals to a recovery home, clinical treatment facility or laboratory, any payer$200,000 and 10 years per occurrence

What the statute says

The Anti-Kickback Statute has a receiving side and a paying side. It reaches anyone who "knowingly and willfully solicits or receives any remuneration (including any kickback, bribe, or rebate) directly or indirectly, overtly or covertly, in cash or in kind" in return for referring a patient, or for "purchasing, leasing, ordering, or arranging for or recommending" any item or service "for which payment may be made in whole or in part under a Federal health care program", and anyone who offers or pays remuneration to induce those things (42 U.S.C. 1320a-7b(b)). The penalty is a felony with a fine of up to $100,000, prison of up to 10 years, or both.

Three more parts of the section matter in practice. Intent: "a person need not have actual knowledge of this section or specific intent to commit a violation of this section" (subsection (h)). False claims: "a claim that includes items or services resulting from a violation of this section constitutes a false or fraudulent claim" under the False Claims Act (subsection (g)). And the definition: a "Federal health care program" is any plan or program providing health benefits that the United States funds directly, in whole or in part (other than the federal employees' plan), or any state health care program such as Medicaid (subsection (f)).

When a GLP-1 or peptide program is inside it

Everything turns on whether a federal program pays for any item or service in the arrangement. Medicare Part D cannot cover drugs "when used for anorexia, weight loss, or weight gain" (42 U.S.C. 1395w-102(e)(2)(A), cross-referencing 1396r-8(d)(2)(A)), but it covers GLP-1s for other medically accepted indications. CMS told Part D plans on June 10, 2026 that patients prescribed Wegovy "to reduce the risk of major adverse cardiovascular events" in adults with established cardiovascular disease and obesity or overweight "should continue to receive coverage through Medicare Part D" (CMS).

Weight management itself now has a federal route. The Medicare GLP-1 Bridge, a demonstration that runs "between July 1, 2026, and December 31, 2027", covers Foundayo, Wegovy and the Zepbound KwikPen when prescribed for weight management, with prior authorization (CMS); CMS announced it as access "for $50 per month" (CMS, May 6, 2026). CMS's BALANCE model lets state Medicaid agencies cover GLP-1s for weight management from May 2026 (CMS). In North Carolina, NC Medicaid stopped covering GLP-1s for obesity on October 1, 2025 and reinstated that coverage effective December 12, 2025 (NC Medicaid). No compounded product is on the Bridge or BALANCE drug lists.

In our reading, a cash-only compounded GLP-1 or peptide program that never bills, and never causes a claim to, Medicare, Medicaid, TRICARE or another federally funded program is generally outside the federal statute, because the payable-by-a-federal-program element is missing. Two cautions. A clinic that also sees Medicare or Medicaid patients, for a branded GLP-1 or for anything else, is inside it for those patients. And OIG has warned that "an attempt to carve out Federal health care program beneficiaries" from an arrangement "may still result in criminal, civil, or administrative liability" (OIG, July 20, 2022).

The safe harbors a clinic actually uses

OIG's safe harbors at 42 CFR 1001.952 describe payments that are not "remuneration". Three matter most to a GLP-1 or peptide clinic.

The personal services and management contracts safe harbor, paragraph (d), covers the medical director agreement, the management company agreement and most vendor contracts. The agreement must be in writing and signed, cover all the services the agent provides and specify them, run at least one year, and need no more services than are "reasonably necessary to accomplish the commercially reasonable business purpose". The key condition is pay: "the methodology for determining the compensation paid to the agent over the term of the agreement is set in advance, is consistent with fair market value in arm's-length transactions, and is not determined in a manner that takes into account the volume or value of any referrals or business otherwise generated between the parties" that a federal program pays for. Since January 19, 2021 the methodology, rather than the aggregate amount, has to be set in advance (85 FR 77684). Payments from "a pharmacy that primarily compounds drugs or primarily dispenses compounded drugs" are excluded from the outcomes-based payment protection in the same paragraph.

Under the employee safe harbor, paragraph (i), amounts an employer pays a bona fide employee for furnishing covered items or services are not remuneration. A clinic that wants to pay staff by the patient is usually better off employing them than contracting with them, though state fee-splitting rules still apply.

Under the referral services safe harbor, paragraph (f), a referral service is protected only if it takes every qualified participant, charges every participant equally based on its operating cost, "and not on the volume or value of any referrals", leaves the participant free to serve the patient as it chooses, and makes written disclosures to each person, including whether the participant paid a fee. A pay-per-lead marketer does not meet that description. An arrangement outside every safe harbor is not automatically illegal; in our reading it is judged on its own facts, which is why the structure and the paperwork matter.

Telehealth arrangements

Much GLP-1 and peptide prescribing runs through telehealth platforms, and OIG's Special Fraud Alert of July 20, 2022 lists characteristics it treats as suspect in arrangements between practitioners and "purported telemedicine companies" (OIG). Among them: patients "identified or recruited" through advertising "for free or low out-of-pocket cost items or services"; a practitioner who lacks "sufficient contact with or information from the purported patient to meaningfully assess the medical necessity"; a company that "compensates the Practitioner based on the volume of items or services ordered or prescribed"; a company that "only furnishes one product or a single class of products", restricting the practitioner to "a predetermined course of treatment"; and no expectation that the practitioner follows up. OIG says the list is illustrative, that no single factor decides the question, and that the alert "is not intended to discourage legitimate telehealth arrangements." A single-product GLP-1 platform that pays prescribers per approval has several of these features at once and should be structured with them in mind. More in telehealth and MSO structures.

Free items and discounts for patients

A separate civil law reaches remuneration to a Medicare or state health care program patient that the giver "knows or should know is likely to influence" the patient to choose a particular provider for items or services those programs pay for (42 U.S.C. 1320a-7a(a)(5)). "Remuneration" includes waived coinsurance and deductibles and "transfers of items or services for free or for other than fair market value" (subsection (i)(6)). OIG's policy statement of December 7, 2016 reads "nominal value" as "no more than $15 per item or $75 in the aggregate per patient on an annual basis", and the items "may not be cash or cash equivalents" (OIG). A free first month or a waived copay for a Medicare patient on a branded GLP-1 needs that analysis; a discount for a cash patient does not, though the advertising rules still do.

EKRA and laboratory testing

The Eliminating Kickbacks in Recovery Act of 2018 is narrower in who it covers and wider in who pays. It reaches anyone who knowingly and willfully pays or receives remuneration "in return for referring a patient or patronage to a recovery home, clinical treatment facility, or laboratory", for services covered by a "health care benefit program", which means "any public or private plan or contract" (18 U.S.C. 220; 18 U.S.C. 24(b)). The maximum is $200,000 and 10 years for each occurrence. A "clinical treatment facility" in EKRA is a substance-use treatment setting, so in our reading the law rarely reaches a weight-loss or peptide clinic directly; it can reach a clinic or marketer paid by a laboratory for the lab panels it orders, whether a public or a private plan covers the tests.

North Carolina

The Medical Board's position does not turn on a federal payer. Its statement on referral fees and fee splitting (adopted November 1993, amended September 2021) says "payment by or to a licensee solely for the referral of a patient is unethical", that "referral fees are prohibited by state law pursuant to N.C. Gen. Stat. § 90-401", and that, "except in instances permitted by law (N.C. Gen. Stat. § 55B-14(c)), it is the position of the Board that a licensee cannot share revenue on a percentage basis with a non-licensee" (NCMB). The statement is not limited to any payer, so a cash-only clinic in Charlotte that pays a marketer per patient, or splits its revenue with a management company, still has a state-law problem. The fee-splitting point is where most management structures need the most work; see clinics and med spas and opening a peptide clinic: the legal checklist.

How the cases look

The federal prosecutions closest to this market involve telemedicine and compounded drugs. On June 30, 2026 the owner of a telemedicine company was sentenced to 120 months in prison and ordered to pay $66 million in restitution; prosecutors said he and others "paid illegal kickbacks to medical providers to sign orders for orthotic braces and prescriptions" (DOJ). On October 15, 2026 the owner of a software platform that connected pharmacies, equipment suppliers and marketers with telemedicine companies was sentenced to 19 years after a jury convicted him, among other counts, of conspiring to pay and receive kickbacks (DOJ). And on February 24, 2026 a Texas physician convicted of accepting bribes from pharmacy owners to prescribe compounded creams was sentenced to 102 months (DOJ).

We found no federal kickback prosecution involving GLP-1s or peptides at DOJ's or OIG's own sites as of November 4, 2026. The pattern in the cases that exist is the one a GLP-1 platform can drift into: pay tied to each order, prescribers with little contact with the patient, and a single product.

Common questions

What is the Anti-Kickback Statute?

A federal criminal law, 42 U.S.C. 1320a-7b(b), that makes it a felony to knowingly and willfully offer, pay, solicit or receive anything of value to induce or reward referrals, or the ordering or recommending of items or services, paid for in whole or in part by Medicare, Medicaid or another federal health care program.

Does the Anti-Kickback Statute apply to cash-pay GLP-1 or peptide clinics?

In our reading, generally not to a program that never bills or causes a claim to a federal program, because federal payment is an element of the offense. It does apply to any Medicare or Medicaid business the clinic has, OIG warns that carving out federal patients may still create liability, and the North Carolina Medical Board's referral-fee and fee-splitting statement is not limited to any payer.

What are the penalties for violating the Anti-Kickback Statute?

Criminally, a felony with a fine of up to $100,000 and up to 10 years in prison. Civilly, a penalty of $127,973 per act after the inflation adjustment plus up to three times the remuneration, exclusion from federal health care programs, and False Claims Act exposure for the resulting claims.

Can a clinic pay a marketer per patient or per lead?

Where federal program business is involved, a fee that rises with the number of patients sent does not fit the personal services safe harbor and is the kind of payment the statute targets. In North Carolina the Medical Board treats payment solely for a referral as unethical and prohibited by state law, and its statement is not limited to any payer.

Can a telehealth company pay its prescribers per consult or per prescription?

OIG lists pay "based on the volume of items or services ordered or prescribed" as a suspect characteristic of telemedicine arrangements. It is not automatically illegal, but it should be replaced or justified, typically with fair-market-value pay set in advance for time and services.

What is EKRA, and does it apply to clinics?

The Eliminating Kickbacks in Recovery Act, 18 U.S.C. 220, bans kickbacks for referrals to recovery homes, substance-use treatment facilities and laboratories under any public or private plan. It rarely reaches a weight-loss or peptide clinic directly, but it can reach payments a laboratory makes for the lab work a clinic orders.

Is the Anti-Kickback Statute the same as the Stark law?

No. Stark separately bars a physician's Medicare-payable referrals for designated health services to an entity with which the physician has a financial relationship, regardless of intent. The Anti-Kickback Statute requires knowing and willful conduct and reaches anyone who pays or receives, not only physicians. See the Stark law explained.

Update log

  • November 4, 2026. Published. The statutes (uscode.house.gov, current through Pub. L. 119-124), 42 CFR 1001.952 and 45 CFR 102.3 (eCFR, November 2, 2026), the OIG alert and policy statement, the CMS Bridge and BALANCE pages, NC Medicaid's notice, the Medical Board statement and the three DOJ releases read at the source November 4, 2026. North Carolina's statutes are described as the Medical Board describes them.

Sources

Related

Published November 4, 2026; updated November 4, 2026. General information, not legal advice. See the disclaimer.

Paying marketers, prescribers or a management company?

DPS Law structures and reviews management, medical director, telehealth and marketing agreements for clinics under North Carolina and federal law. For another state's referral or fee-splitting rules, talk to a lawyer licensed in that state.

Peptide attorney in Charlotte, NC